Orlando, FL-In patients with metastatic renal cell carcinoma, adjuvant interleukin-2 (IL-2) after cytoreductive nephrectomy appears to offer a superior survival benefit over nephrectomy followed by interferon alpha-2b, according to a report presented here at the American Society of Clinical Oncology annual meeting.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.